Table 2 Characteristics of the subjects enrolled in the test seta.

From: Blood biomarkers indicate that the preclinical stages of Alzheimer's disease present overlapping molecular features

TEST SET

1: CN

2: SMD

3: MCI

4: AD

p value 1–2; 1–3; 1–4

p value 2–3; 2–4; 3–4

Anthropometric data

No

23

20

19

19

-

-

Age (mean ± SD; y)

62.8 ± 6.4

64.2 ± 7.3

68.3 ± 5.4

77.5 ± 7.4

0.5; 0.005; < 0.001

0.06; < 0.001; < 0.001

Sex (F; %/M; %)

11; 47.8/12; 52.2

12; 60.0/8; 40.0

10; 52.6/9; 47.4

12; 63.2/7; 36.8

 > 0.99; > 0.99; > 0.99

 > 0.99; > 0.99; > 0.99

Education level (mean ± SD; y)

12.9 ± 2.6

12.0 ± 2.8

9.5 ± 3.9

9.0 ± 4.8

0.28; 0.001; 0.001

 < 0.001; < 0.001; < 0.001

BMI (mean ± SD; kg/m2)

28.8 ± 3.

27.0 ± 3.2

26.9 ± 3.9

24.4 ± 4.4

0.08; 0.09; 0.007

0.9; 0.04; 0.07

MMSE (mean ± SD; score)

29.4 ± 2.7

29.2 ± 1.8

24.9 ± 5.5

15.4 ± 7.1

0.78; 0.001; < 0.001

 < 0.001; < 0.001; < 0.001

Familial AD (n; %)

2; 8.7

2; 10.0

2; 10.5

2; 10.5

 > 0.99; > 0.99; > 0.99

 > 0.99; > 0.99; > 0.99

Familial Dementia (n; %)

1; 4.3

3; 15.0

4; 21.0

3; 15.8

0.34;0.18; 0.33

 > 0.99; > 0.99; > 0.99

Familial Neurodegenerative Diseases (n; %)

1; 4.3

3; 15.0

2; 10.5

3; 15.8

0.34; 0.68; 0.33

 > 0.99; > 0.99; > 0.99

Smokeb (n; %)

8; 34.8

8; 40.0

5; 26.3

2; 10.5

0.9; 0.75; 0.52

0.74; 0.15; 0.42

Dyslipidemia (n; %)

8; 34.8

6; 30.0

5; 26.3

4; 21.0

 > 0.99; 0.75; 0.52

 > 0.99; 0.73; > 0.99

Diabetes (n; %)

4; 17.4

2; 10.0

2; 10.5

2; 10.5

0.67; 0.66; 0.67

 > 0.99; > 0.99; > 0.99

Hypertension (n; %)

8; 34.8

7; 35.0

8; 42.1

4; 21.0

 > 0.99; 0.99; 0.52

 > 0.99; 0.51; 0.42

Arrhythmia (n; %)

2; 8.7

5; 25.0

2; 10.5

0; 0.0

0.41; > 0.99; 0.5

0.4; 0.06; 0.48

AED (n; %)

0; 0.0

0; 0.0

0; 0.0

4; 21.0

 > 0.99; > 0.99; 0.1

 > 0.99; 0.3; 0.2

Myocardial Infarction (n; %)

1; 4.3

1; 5.0

1; 5.3

1; 5.3

 > 0.99; > 0.99; > 0.99

 > 0.99; > 0.99; > 0.99

Heart Failurec (n; %)

1; 4.3

1; 5.0

1; 5.3

1; 5.3

 > 0.99; > 0.99; > 0.99

 > 0.99; > 0.99; > 0.99

TIA/Stroke (n; %)

0; 0.0

1; 5.0

2; 10.5

0; 0.0

 > 0.99; > 0.99; > 0.99

 > 0.99; > 0.99; > 0.99

Chronic Kidney Diseased (n; %)

0; 0.0

1; 5.0

0; 0.0

1; 5.3

 > 0.99; > 0.99; > 0.99

 > 0.99; > 0.99; > 0.99

Prior Tumors (n; %)

3; 13.0

3; 15.0

1; 5.3

2; 10.5

 > 0.99; > 0.99; > 0.99

 > 0.99; > 0.99; > 0.99

Neurodegenerative Diseases (n; %)

0; 0.0

0; 0.0

1; 5.3

0; 0.0

 > 0.99; > 0.99; > 0.99

 > 0.99; > 0.99; > 0.99

Alcool > 4 unit/day (n; %)

0; 0.0

0; 0.0

0; 0.0

0; 0.0

 > 0.99; > 0.99; > 0.99

 > 0.99; > 0.99; > 0.99

Carotid Atheroma or Aneurysms (n; %)

2; 8.7

1; 5.0

1; 5.3

2; 10.5

 > 0.99; > 0.99; > 0.99

 > 0.99; > 0.99; > 0.99

Venous Insufficiency (n; %)

2; 8.7

2; 10.0

0; 0.0

2; 10.5

 > 0.99; 0.49; > 0.99

 > 0.99; 0.49; 0.5

Asthma, COPD, O2 herapy (n; %)

1; 4.3

1; 5.0

1; 5.3

1; 5.3

 > 0.99; > 0.99; > 0.99

 > 0.99; > 0.99; > 0.99

Dysthyroidism (n; %)

8; 34.8

4; 20.0

2; 10.5

1; 5.3

0.51; 0.17; 0.07

0.50; 0.30; 0.80

Cirrhosis, Steatosis, Biliary Lithiasis (n; %)

3; 13.0

2; 10.0

0; 0.0

1; 5.3

 > 0.99; 0.25; 0.33

0.49; > 0.99; > 0.99

Previous Surgery (n; %)

11; 47.8

8; 40.0

3; 15.8

3; 15.8

0.78; 0.2; 0.2

0.3; 0.3; > 0.99

Pharmacological Treatment

Antihypertensive (n; %)

9; 39.1

9; 45.0

8; 42.1

6; 31.6

 > 0.99; > 0.99; 0.77

0.76; 0.76; 0.75

Lipid-lowering (n; %)

6; 26.1

5; 25.0

5; 26.3

2; 10.5

 > 0.99; > 0.99; 0.44

0.99; 0.42; 0.42

Hypoglycemic (n; %)

3; 13.0

2; 10.0

1; 5.3

1; 5.3

 > 0.99; 0.44; 0.44

0.51; 0.51; > 0.99

Antiplatelet (n; %)

4; 17.4

3; 15.0

1; 5.3

4; 21.0

 > 0.99; 0.37; > 0.99

 > 0.99; > 0.99; 0.35

Thyroid Hormones (n; %)

5; 21.7

4; 20.0

1; 5.3

0; 0.0

 > 0.99; 0.37; 0.07

0.11; 0.1; > 0.99

Antianxiety (n; %)

1; 4.3

1; 5.0

2; 10.5

4; 21.0

0.36; 0.68; > 0.99

 > 0.99; 0.34; 0.66

Antidepressant (n; %)

2; 8.7

1; 5.0

2; 10.5

6; 31.6

 > 0.99; > 0.99; 0.24

 > 0.99; 0.1; 0.25

Neurotrophic (n; %)

0; 0.0

0; 0.0

1; 5.3

3; 15.8

 > 0.99; 0.46; 0.1

 > 0.99; 0.23; 0.6

I-AChE (n; %)

0; 0.0

0; 0.0

0; 0.0

2; 10.5

 > 0.99; 0.8; 0.7

 > 0.99; 0.48; 0.4

  1. Bold values are statistically significant (p < 0.05).
  2. aCN, cognitively normal; SMD, subjective memory decline; MCI, mild cognitive impairment; AD, Alzheimer’s disease; BMI, Body mass index; MMSE, Mini Mental State Examination; AED, antiepileptic drugs; TIA, Transient Ischemic Attack; I-AChE, Acetylcholinesterase Inhibitors.
  3. bCurrent or former smokers.
  4. cSubjects in NYHA (New York Heart Association) classes I–II.
  5. dSubjects with glomerular filtration rate (GFR) > 30 ml/min/1.73 m2.